NDAORALCAPSULEPriority Review
Approved
Aug 2011
Lifecycle
Peak
Competitive Pressure
8/100
Clinical Trials
20
Data completeness
5/8 — Partial
Priority Review
XALKORI (crizotinib) by Pfizer is cytochrome p450 3a inhibitors [moa]. Approved for non-small cell lung cancer, anaplastic large cell lymphoma, inflammatory myofibroblastic tumor. First approved in 2011.
Drug data last refreshed 20h ago
Mechanism of Action
Cytochrome P450 3A Inhibitors
Pharmacologic Class:
Kinase Inhibitor
Worked on XALKORI at Pfizer? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.